<?xml version="1.0" encoding="UTF-8"?>
<p>This article was developed with funding support awarded to Cal PREPARE, University of California at Berkeley Center for Infectious Diseases and Emergency Readiness under cooperative agreements with the US Centers for Disease Control and Prevention (CDC) grant number 5P01TP000295 (Preparedness and Emergency Response Research Center). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or other partner organizations. The authors would like to acknowledge all of those individuals who participated in this research, especially the LHD representatives, the members of the Pandemic Influenza Vaccine and Antiviral Advisory (PIVA) Advisory Group. We would also like to acknowledge the following individuals for reviewing survey materials and providing editorial support: Dr. Deborah Miller, Dr. Harvey Kayman, Mark Hunter, Donata Nilsen, Adam Crawley, and Jane Yang. Finally, we would like to thank Dr. Gwendolyn Hammer, Lisa Goldberg, and the California Department of Public Health for establishing the Pandemic Influenza Vaccine and Antiviral Advisory (PIVA) Advisory Group and developing the related decision-making methodology.</p>
